Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS

References

• Jeffrey SS, Lonning PE, Hillner BE. Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Net 2005; 3:291-300; PMID:16002001
   PubMedGoogle Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12; PMID:2470152; http://dx.doi.org/10.1126/science.2470152
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9:16-32; PMID:22124364; http://dx.doi.org/10.1038/nrclinonc.2011.177
   PubMed Web of Science ®Google Scholar
• Higa GM, Abraham J. Lapatinib in the treatment of breast cancer. Exp Rev Anticancer Ther 2007; 7:1183-92; PMID:17892419; http://dx.doi.org/10.1586/14737140.7.9.1183
   PubMed Web of Science ®Google Scholar
• Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64:6652-9; PMID:15374980; http://dx.doi.org/10.1158/0008-5472.CAN-04-1168
   PubMed Web of Science ®Google Scholar
• Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008; 68:7905-14; PMID:18829547; http://dx.doi.org/10.1158/0008-5472.CAN-08-0499
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66:1630-9; PMID:16452222; http://dx.doi.org/10.1158/0008-5472.CAN-05-1182
   PubMed Web of Science ®Google Scholar
• Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21:6255-63; PMID:12214266; http://dx.doi.org/10.1038/sj.onc.1205794
   PubMed Web of Science ®Google Scholar
• Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85-94; PMID:12467226
   PubMed Web of Science ®Google Scholar
• Campone M, Juin P, Andre F, Bachelot T. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. Crit Rev Oncol/Hematol 2011; 78:195-205; PMID:20684884; http://dx.doi.org/10.1016/j.critrevonc.2010.04.012
   PubMed Web of Science ®Google Scholar
• Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008; 22:999-1012; PMID:18618524; http://dx.doi.org/10.1002/ptr.2399
   PubMed Web of Science ®Google Scholar
• Singhal KC. Anthelmintic activity of berberine hydrochloride against Syphacia obvelata in mice. Indian J Exp Biol 1976; 14:345-7; PMID:1033150
   PubMed Web of Science ®Google Scholar
• Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol 2009; 126:5-17; PMID:19686830; http://dx.doi.org/10.1016/j.jep.2009.08.009
   PubMed Web of Science ®Google Scholar
• Kim S, Han J, Lee SK, Choi MY, Kim J, Lee J, Jung SP, Kim JS, Kim JH, Choe JH, et al. Berberine suppresses the TPA-induced MMP-1 and MMP-9 expressions through the inhibition of PKC-alpha in breast cancer cells. J Surg Res 2012; 176:e21-9; PMID:22381172; http://dx.doi.org/10.1016/j.jss.2011.11.1041
   PubMedGoogle Scholar
• Kim JB, Ko E, Han W, Shin I, Park SY, Noh DY. Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells. Planta medica 2008; 74:1693-700; PMID:18951337; http://dx.doi.org/10.1055/s-0028-1088313
   PubMed Web of Science ®Google Scholar
• Kim DW, Ahan SH, Kim TY. Enhancement of Arsenic Trioxide (As(2)O(3))- Mediated Apoptosis Using Berberine in Human Neuroblastoma SH-SY5Y Cells. J Korean Neurosurg Soc 2007; 42:392-9; PMID:19096576; http://dx.doi.org/10.3340/jkns.2007.42.5.392
   PubMed Web of Science ®Google Scholar
• Liu J, He C, Zhou K, Wang J, Kang JX. Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cells. Biochem Biophys Res Commun 2009; 378:174-8; PMID:19000652; http://dx.doi.org/10.1016/j.bbrc.2008.10.169
   PubMed Web of Science ®Google Scholar
• Formentini L, Sanchez-Arago M, Sanchez-Cenizo L, Cuezva JM. The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response. Mol Cell 2012; 45:731-42; PMID:22342343; http://dx.doi.org/10.1016/j.molcel.2012.01.008
   PubMed Web of Science ®Google Scholar
• Gnocchi D, Leoni S, Incerpi S, Bruscalupi G. 3,5,3′-triiodothyronine (T3) stimulates cell proliferation through the activation of the PI3K/Akt pathway and reactive oxygen species (ROS) production in chick embryo hepatocytes. Steroids 2012; 77:589-95; PMID:22366194; http://dx.doi.org/10.1016/j.steroids.2012.01.022
   PubMed Web of Science ®Google Scholar
• Lenaz G. Mitochondria and reactive oxygen species. Which role in physiology and pathology? Adv Exp Med Biol 2012; 942:93-136; PMID:22399420; http://dx.doi.org/10.1007/978-94-007-2869-1_5
   PubMed Web of Science ®Google Scholar
• Kuo PL, Chen CY, Hsu YL. Isoobtusilactone A induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells. Cancer Res 2007; 67:7406-20; PMID:17671211; http://dx.doi.org/10.1158/0008-5472.CAN-07-1089
   PubMed Web of Science ®Google Scholar
• Xie J, Xu Y, Huang X, Chen Y, Fu J, Xi M, Wang L. Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway. Tumour Biol 2015; 36:1279-88; PMID:25352028; http://dx.doi.org/10.1007/s13277-014-2754-7
   PubMed Web of Science ®Google Scholar
• Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 2006; 38:769-89; PMID:17145701; http://dx.doi.org/10.1080/03602530600971974
   PubMed Web of Science ®Google Scholar
• Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A 1996; 93:14960-5; PMID:8962164; http://dx.doi.org/10.1073/pnas.93.25.14960
   PubMed Web of Science ®Google Scholar
• Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, Harada T, Yamamoto M. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001; 59:169-77; PMID:11134556; http://dx.doi.org/10.1093/toxsci/59.1.169
   PubMed Web of Science ®Google Scholar
• Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci U S A 2001; 98:4611-6; PMID:11287661; http://dx.doi.org/10.1073/pnas.081082098
   PubMed Web of Science ®Google Scholar
• Li YJ, Takizawa H, Azuma A, Kohyama T, Yamauchi Y, Takahashi S, Yamamoto M, Kawada T, Kudoh S, Sugawara I. Disruption of Nrf2 enhances susceptibility to airway inflammatory responses induced by low-dose diesel exhaust particles in mice. Clin Immunol 2008; 128:366-73; PMID:18614404; http://dx.doi.org/10.1016/j.clim.2008.05.005
   PubMed Web of Science ®Google Scholar
• Iizuka T, Ishii Y, Itoh K, Kiwamoto T, Kimura T, Matsuno Y, Morishima Y, Hegab AE, Homma S, Nomura A, et al. Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells 2005; 10:1113-25; PMID:16324149; http://dx.doi.org/10.1111/j.1365-2443.2005.00905.x
   PubMed Web of Science ®Google Scholar
• Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, Yamamoto M. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol 2001; 173:154-60; PMID:11437637; http://dx.doi.org/10.1006/taap.2001.9176
   PubMed Web of Science ®Google Scholar
• Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 2001; 98:3410-5; PMID:11248092; http://dx.doi.org/10.1073/pnas.051618798
   PubMed Web of Science ®Google Scholar
• Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, Shimazui T, Akaza H, Yamamoto M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004; 64:6424-31; PMID:15374950; http://dx.doi.org/10.1158/0008-5472.CAN-04-1906
   PubMed Web of Science ®Google Scholar
• Mao L, Wang H, Qiao L, Wang X. Disruption of Nrf2 enhances the upregulation of nuclear factor-kappaB activity, tumor necrosis factor-alpha, and matrix metalloproteinase-9 after spinal cord injury in mice. Mediators of inflammation 2010; 2010:238321; PMID:20862369; http://dx.doi.org/10.1155/2010/238321
   PubMed Web of Science ®Google Scholar
• Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008; 29:1235-43; PMID:18413364; http://dx.doi.org/10.1093/carcin/bgn095
   PubMed Web of Science ®Google Scholar
• Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid-Based Complement Alternat Med 2014; 2014:289264; PMID:24669227; http://dx.doi.org/10.1155/2014/289264
   PubMed Web of Science ®Google Scholar
• Robidoux A, Tang G, Rastogi P, Geyer CE, Jr., Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14:1183-92; PMID:24095300; http://dx.doi.org/10.1016/S1470-2045(13)70411-X
   PubMed Web of Science ®Google Scholar
• Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009; 69:6871-8; PMID:19671800; http://dx.doi.org/10.1158/0008-5472.CAN-08-4490
   PubMed Web of Science ®Google Scholar
• Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L. RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer Lett 2013; 340:43-50; PMID:23811285; http://dx.doi.org/10.1016/j.canlet.2013.06.022
   PubMed Web of Science ®Google Scholar
• Brady SW, Zhang J, Seok D, Wang H, Yu D. Enhanced PI3K p110alpha signaling confers acquired lapatinib resistance that can be effectively reversed by a p110alpha-selective PI3K inhibitor. Mol Cancer Ther 2014; 13:60-70; PMID:24249715; http://dx.doi.org/10.1158/1535-7163.MCT-13-0518
   PubMed Web of Science ®Google Scholar
• Chen S, Zhu X, Qiao H, Ye M, Lai X, Yu S, Ding L, Wen A, Zhang J. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib. Tumour Biol 2016 Feb; 37(2):2321-31; PMID:26369543; http://dx.doi.org/10.1007/s13277-015-3800-9
   Web of Science ®Google Scholar
• Tan W, Zhong Z, Wang S, Suo Z, Yang X, Hu X, Wang Y. Berberine Regulated Lipid Metabolism in the Presence of C75, Compound C, and TOFA in Breast Cancer Cell Line MCF-7. Evid-Based Complement Alternative Med 2015; 2015:396035; PMID:26351511; http://dx.doi.org/10.1155/2015/396035
   PubMed Web of Science ®Google Scholar
• Mohanty S, Saha S, Md SHD, Adhikary A, Mukherjee S, Manna A, Chakraborty S, Mazumdar M, Ray P, Das K, et al. ROS-PIASgamma cross talk channelizes ATM signaling from resistance to apoptosis during chemosensitization of resistant tumors. Cell Death Dis 2014; 5:e1021; PMID:24457965; http://dx.doi.org/10.1038/cddis.2013.534
   Google Scholar
• Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 2000; 29:323-33; PMID:11035261; http://dx.doi.org/10.1016/S0891-5849(00)00302-6
   PubMed Web of Science ®Google Scholar
• Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7:97-110; PMID:15158766; http://dx.doi.org/10.1016/j.drup.2004.01.004
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang A, Xia T, He P. Effects of fluoride on DNA damage, S-phase cell-cycle arrest and the expression of NF-kappaB in primary cultured rat hippocampal neurons. Toxicol Lett 2008; 179:1-5; PMID:18485627; http://dx.doi.org/10.1016/j.toxlet.2008.03.002
   PubMed Web of Science ®Google Scholar
• Tkachev VO, Menshchikova EB, Zenkov NK. Mechanism of the Nrf2/Keap1/ARE signaling system. Biochem Biokhimiia 2011; 76:407-22; PMID:21585316; http://dx.doi.org/10.1134/S0006297911040031
   PubMed Web of Science ®Google Scholar
• Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jaworski T, Tobón-Velasco JC, Devijver H, García-Mayoral MF, Van Leuven F, et al. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/beta-TrCP axis. Mol Cell Biol 2012; 32:3486-99; PMID:22751928; http://dx.doi.org/10.1128/MCB.00180-12
   PubMed Web of Science ®Google Scholar
• DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475:106-9; PMID:21734707; http://dx.doi.org/10.1038/nature10189
   PubMed Web of Science ®Google Scholar
• Matkar S, Sharma P, Gao S, Gurung B, Katona BW, Liao J, Muhammad AB, Kong XC, Wang L, Jin G, et al. An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis. Cancer Cell 2015; 28:472-85; PMID:26461093; http://dx.doi.org/10.1016/j.ccell.2015.09.005
   PubMed Web of Science ®Google Scholar
• Zhang J, Cao H, Zhang B, Cao H, Xu X, Ruan H, Yi T, Tan L, Qu R, Song G, et al. Berberine potently attenuates intestinal polyps growth in ApcMin mice and familial adenomatous polyposis patients through inhibition of Wnt signalling. J Cell Mol Med 2013; 17:1484-93; PMID:24015932; http://dx.doi.org/10.1111/jcmm.12119
   PubMed Web of Science ®Google Scholar